Goldman Sachs’s Filana Therapeutics FLNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $69.8K | Buy |
41,324
+8,335
| +25% | +$17.2K | ﹤0.01% | 6258 |
|
|
2025
Q4 | $65.3K | Sell |
32,989
-439,871
| -93% | -$1.41M | ﹤0.01% | 6257 |
|
|
2025
Q3 | $1.38M | Sell |
472,860
-140,283
| -23% | -$323K | ﹤0.01% | 4807 |
|
|
2025
Q2 | $1.11M | Buy |
613,143
+116,830
| +24% | +$208K | ﹤0.01% | 4617 |
|
|
2025
Q1 | $744K | Buy |
496,313
+217,404
| +78% | +$549K | ﹤0.01% | 4920 |
|
|
2024
Q4 | $658K | Buy |
278,909
+125,970
| +82% | +$2.21M | ﹤0.01% | 5079 |
|
|
2024
Q3 | $4.5M | Buy |
152,939
+67,694
| +79% | +$1.56M | ﹤0.01% | 3439 |
|
|
2024
Q2 | $1.05M | Buy |
85,245
+32,414
| +61% | +$683K | ﹤0.01% | 4394 |
|
|
2024
Q1 | $1.07M | Sell |
52,831
-108,828
| -67% | -$2.51M | ﹤0.01% | 4303 |
|
|
2023
Q4 | $3.64M | Buy |
161,659
+108,456
| +204% | +$2.29M | ﹤0.01% | 3428 |
|
|
2023
Q3 | $885K | Sell |
53,203
-12,317
| -19% | -$244K | ﹤0.01% | 4353 |
|
|
2023
Q2 | $1.61M | Buy |
65,520
+2,007
| +3% | +$48.3K | ﹤0.01% | 4021 |
|
|
2023
Q1 | $1.53M | Sell |
63,513
-95,734
| -60% | -$2.65M | ﹤0.01% | 4065 |
|
|
2022
Q4 | $4.7M | Buy |
159,247
+82,452
| +107% | +$2.96M | ﹤0.01% | 3220 |
|
|
2022
Q3 | $3.21M | Buy |
76,795
+39,238
| +104% | +$1.06M | ﹤0.01% | 3543 |
|
|
2022
Q2 | $1.06M | Sell |
37,557
-1,639
| -4% | -$41.4K | ﹤0.01% | 4571 |
|
|
2022
Q1 | $1.46M | Sell |
39,196
-15,717
| -29% | -$666K | ﹤0.01% | 4522 |
|
|
2021
Q4 | $2.4M | Buy |
54,913
+2,956
| +6% | +$155K | ﹤0.01% | 4101 |
|
|
2021
Q3 | $3.23M | Sell |
51,957
-13,195
| -20% | -$1.1M | ﹤0.01% | 3754 |
|
|
2021
Q2 | $5.57M | Buy |
65,152
+16,838
| +35% | +$902K | ﹤0.01% | 3240 |
|
|
2021
Q1 | $2.17M | Buy |
48,314
+28,866
| +148% | +$1.14M | ﹤0.01% | 3901 |
|
|
2020
Q4 | $133K | Buy |
19,448
+6,905
| +55% | +$61.6K | ﹤0.01% | 5235 |
|
|
2020
Q3 | $144K | Buy |
+12,543
| New | +$56.5K | ﹤0.01% | 5013 |
|
|
2017
Q2 | – | Sell |
-4,798
| Closed | -$30K | – | 6943 |
|
|
2017
Q1 | $30K | Sell |
4,798
-2,438
| -34% | -$11.1K | ﹤0.01% | 6423 |
|
|
2016
Q4 | $29K | Sell |
7,236
-7,579
| -51% | -$35.1K | ﹤0.01% | 6542 |
|
|
2016
Q3 | $104K | Buy |
14,815
+12,036
| +433% | +$199K | ﹤0.01% | 6210 |
|
|
2016
Q2 | $43K | Buy |
+2,779
| New | +$44.1K | ﹤0.01% | 6473 |
|
|
2016
Q1 | – | Sell |
-4,194
| Closed | -$51K | – | 7293 |
|
|
2015
Q4 | $51K | Sell |
4,194
-12,317
| -75% | -$163K | ﹤0.01% | 6532 |
|
|
2015
Q3 | $212K | Sell |
16,511
-34,851
| -68% | -$440K | ﹤0.01% | 5974 |
|
|
2015
Q2 | $622K | Buy |
51,362
+44,175
| +615% | +$605K | ﹤0.01% | 4965 |
|
|
2015
Q1 | $95K | Sell |
7,187
-1,749
| -20% | -$23.6K | ﹤0.01% | 6439 |
|
|
2014
Q4 | $127K | Buy |
+8,936
| New | +$155K | ﹤0.01% | 6465 |
|
|
2013
Q4 | – | Sell |
-26,196
| Closed | -$499K | – | 6786 |
|
|
2013
Q3 | $499K | Sell |
26,196
-972
| -4% | -$17K | ﹤0.01% | 5150 |
|
|
2013
Q2 | $420K | Buy |
+27,168
| New | +$574K | ﹤0.01% | 5074 |
|
Other funds holding FLNA
VCM
GC
Goldman Sachs's FLNA Position: Q1 2026 in Review
Goldman Sachs increased its Filana Therapeutics (FLNA) stake by 25% in Q1 2026, buying an estimated $17.2K and bringing the position to 41,324 shares worth $69.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6258.
Goldman Sachs first reported a position in FLNA in Q2 2013 and has held it in 34 quarters since. The position peaked at $5.57M in Q2 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.
- Goldman Sachs held 41,324 shares of Filana Therapeutics worth $69.8K as of Q1 2026.
- Goldman Sachs bought 8,335 Filana Therapeutics shares in Q1 2026, an estimated $17.2K.
- Filana Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6258 holding.
- Goldman Sachs first reported a position in Filana Therapeutics in Q2 2013 and has held it in 34 quarters since.
- Goldman Sachs's Filana Therapeutics position peaked at $5.57M in Q2 2021.
- 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.